Mass General Brigham
Boston, Massachusetts, 02215, United States
Location status: Recruiting
Location contact
Dennis Munoz-Vergara, DVM, MS, MPH
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06949007
The overall goal of this project is to complete a pilot feasibility randomized controlled trial (RCT) to inform a future fully-powered translational study evaluating yoga for management and resolution of persistent-post surgical pan (PPSP) and the role of biological, psychophysical, and psychosocial modulators in PPSP resolution.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02215, United States
Location status: Recruiting
Dennis Munoz-Vergara, DVM, MS, MPH
PRINCIPAL_INVESTIGATOR
More than 100 million people in the United States (US) undergo surgical procedures each year. These individuals are at risk of developing persistent post-surgical pain (PPSP), with estimates as high as 70% for some procedures (e.g., post-thoracotomy, hernial repair, cholecystectomy, cesarean section, sternotomy). PPSP, defined as pain in the surgical area that lasts more than 3 months after surgery, is a unique syndrome of chronic pain. Prior studies suggest that inflammation plays a major role in the development of PPSP, along with peripheral and central sensitization due to nerve damage, and weakening of the endogenous central opioid and endocannabinoid systems. Thus, PPSP provides a unique opportunity that invites translational research.
Currently, the main strategy for managing PPSP is pharmacological treatment. However, long-term use of potent analgesics is associated with untoward side effects (e.g., priming to develop PPSP). A growing body of research supports the benefit of mind-body movement therapies (MBMT), such as yoga, in treating chronic pain; however, little attention has been devoted to adapting a yoga program for the specific needs that PPSP patients may face (e.g., range of motion). Moreover, while randomized controlled trials (RCTs) support that yoga alleviates pain, the mechanisms underlying its therapeutic benefits are largely unclear.
Preclinical and clinical studies suggest yoga has the potential to alter systemic levels of inflammatory mediators (i.e., cytokines and oxylipins) via body movement and stretching. Given that inflammatory processes may contribute to more severe and prolonged pain after surgery, yoga practice may mitigate the development of PPSP via the modulation of circulating levels of inflammatory and endocannabinoid mediators, resulting in endogenous analgesia. Evaluation of the links between yoga and post-surgical pain, with modulation of systemic levels of these potential mediators, is a novel area of inquiry, which may inform the practical and safe use of yoga in postoperative patients.
This pilot translational RCT proposes comparing a yoga program versus a chronic pain health education (CPHE) program in individuals with PPSP. This pilot RCT will help collect essential preliminary data to inform a future translational trial evaluating a widely available and adaptable intervention (yoga) for a highly prevalent and debilitating pain condition (PPSP) that impacts multiple dimensions of whole-person health.
Multiple indicators of feasibility and acceptability of the intervention and procedures will be evaluated. Upon enrollment, participants (N=50) will be randomly assigned 1:1 to one of the two treatment groups using a permuted block randomization, with block sizes of 2 and 4 to either the yoga group or the health education control group.
Following the study timeline, participants will be asked to complete three assessments: baseline (T1-prior to randomization), post-intervention (T2- ~ 12 weeks post-T1), and 3 months post-intervention (T3- ~24 weeks post-T1). Each assessment will include blood samples for select outcomes related to inflammation (e.g., cytokines), psychophysical assessment of pain and pain sensitivity test (i.e., Quantitative Sensory Testing), psychosocial patient-centered outcomes (i.e., PROMIS-29), clinical neuropathy (i.e., S-LANSS), and self-patient-reported pain interference and severity (i.e., BPI). Participants in the yoga groups (approximately 3 cohorts of 8-9 participants each) will be asked to provide brief feedback on acceptability of session content via a weekly survey.
This study will allow us to address our primary Aim 1: To design and conduct a pilot feasibility RCT of yoga in individuals with PPSP. This aim has three components: a) To adapt a validated yoga program to individuals with PPSP ; b) To assess multiple indicators of feasibility and acceptability, such as recruitment, retention, adherence, and acceptability and; c) To assess feasibility of collecting PPSP-related outcomes. An secondary exploratory Aim 2 will explore the longitudinal relationship between yoga or an education control group on changes in PPSP-related inflammatory markers (e.g., IL-6) and other known psychophysical (i.e., QST), and psychosocial (e.g., PROMIS-29) modulators of PPSP to further inform our conceptual framework and the design of a larger trial assessing the impact of yoga on PPSP resolution.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Duration: 12 weeks; Class length: Three ∼75-minute classes per week. Two in-person/virtual (hybrid), one virtual only (MGB Zoom); Frequency: Three classes per week; Group size: 8-9 PPSP patients.
Other names: Yoga exercise
Duration: 12 weeks (short videos and PowerPoint presentations); Class length: Interactive 15-30 minute education sessions delivered via video conference (i.e., MGB Zoom); Frequency: Three classes per week; Group size: 8-9 PPSP patients.
Other names: CPHE
Time frame: 36 months
≥ 30% of contacted eligible participants will enroll. Assessment Instrument: REDCap report.
Time frame: 36 months
≥65% of randomized participants will attend all study visits and complete all outcome assessments.
Assessment instrument: REDCap Report of three in-person study visits.
Time frame: 36 months
Recruitment will be completed within 18 months (2-3 participants/month).
Assessment instrument: REDCap report.
Time frame: 36 months
≥75% of randomized participants will adhere to the intervention programs. Target: ≥75% Assessment instrument via Mycap survey-Meeting 75% adherence in the 12-week yoga program requires attending at least one class per week for at least 9 weeks. For home practice, 75% adherence (2+ days/week) corresponds to at least 18 sessions over 12 weeks. Participants can meet this goal by virtually attending additional group classes (up to three per week) or by engaging in 15-30 minutes of home practice, recorded in their weekly MyCap survey. Meeting 75% adherence in the 12-week CPHE program requires attending at least one class per week for at least 9 weeks (attendance to weekly PowerPoint presentation and completeness of weekly MyCap survey on CPHE program satisfaction).
Time frame: 36 months
≥80% of participants will rate the intervention favorably. Target: ≥80% Assessment instrument via REDCap survey asking participants to rate (0=not at all to 10=very much) enjoyment, convenience, helpfulness, and overall satisfaction after each session and at T2 (post-intervention).
Time frame: 36 months
≥70% adherence to the structured yoga class components in 10% of observed classes.
Assessment instrument: REDCap Report.
Time frame: 36 months
≥80% of PPSP-related outcome measures will be collected.
Assessment instruments: REDCap report for clinical, psychophysical, and biological outcome collection.
Time frame: 48 months
Descriptive statistics and exploratory treatment assignment effects on clinical outcomes-Brief Pain Inventory (BPI) scores for pain severity (composite of the four pain items-a mean severity score) and interference (mean of the seven interference items).
Assess at baseline (T1), 12-week post-intervention (T2), and 12-week follow-up (T3). Higher scores indicate greater pain.
Time frame: 48 months
Descriptive statistics and exploratory treatment assignment effects on clinical outcomes-PROMIS-29 T scores for the seven domains (Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities).
Assess at baseline (T1), 12-week post-intervention (T2), and 12-week follow-up (T3).
A higher PROMIS T-score represents more of the concept being measured.
Time frame: 48 months
Descriptive statistics and exploratory treatment assignment effects on clinical outcomes-S-LANSS score from 7 items to assess neuropathic symptoms and signs (range 0-24).
Assess at baseline (T1), 12-week post-intervention (T2), and 12-week follow-up (T3).
Higher scores indicate greater neuropathic symptoms and signs.
Time frame: 48 months
Descriptive statistics and exploratory treatment assignment effects on psychophysical outcomes-Brief bedside-adapted Quantitative Sensory Testing (QST): Pinprick applicators (force expressed in Newtons and 3-point ordinal scale: absent, impaired, normal) for TSP. Assess at baseline (T1), 12-week post-intervention (T2), and 12-week follow-up (T3).
Time frame: 48 months
Descriptive statistics and exploratory treatment assignment effects on psychophysical outcomes-Brief bedside-adapted Quantitative Sensory Testing (QST): Pinprick applicators (force expressed in Newtons and 3-point ordinal scale: absent, impaired, normal) for PAS. Assess at baseline (T1), 12-week post-intervention (T2), and 12-week follow-up (T3).
Time frame: 48 months
Descriptive statistics and exploratory treatment assignment effects on psychophysical outcomes-Brief bedside-adapted Quantitative Sensory Testing (QST): Algometer (force expressed in units of kilopascals (kPa) or kg/cm2) for PPTh. Assess at baseline (T1), 12-week post-intervention (T2), and 12-week follow-up (T3).
Time frame: 48 months
Descriptive statistics and exploratory treatment assignment effects on psychophysical outcomes-Brief bedside-adapted Quantitative Sensory Testing (QST): Algometer (force expressed in units of kilopascals (kPa) or kg/cm2) for PPTo. Assess at baseline (T1), 12-week post-intervention (T2), and 12-week follow-up (T3).
Time frame: 48 months
Descriptive statistics and exploratory treatment assignment effects on inflammatory and analgesic mediators: Multi-analyte flow assay (e.g., customized Legendplex) for cytokines (ng or pg/mL). Lipid extraction and LC-MS-MS or ELISA for oxylipins and endocannabinoids (ng or pg/mL).
Assess at baseline (T1), 12-week post-intervention (T2), and 12-week follow-up (T3).
Contact information is provided by the study sponsor or research team.
Dennis Munoz-Vergara, DVM, MS, MPH
CONTACT
Peter Wayne, PhD
CONTACT
Brigham and Women's Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03351309
Persistent Post-surgical Pain, Veterans
Iowa City, Iowa, United States
View Trial DetailsNCT02437188
Acceptance and Commitment Therapy, Chemically-Induced Disorders
Iowa City, Iowa, United States
View Trial Details